1. Home
  2. JHS vs ELTX Comparison

JHS vs ELTX Comparison

Compare JHS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Income Securities Trust

JHS

John Hancock Income Securities Trust

HOLD

Current Price

$11.01

Market Cap

136.5M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$12.06

Market Cap

209.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JHS
ELTX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.5M
209.9M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
JHS
ELTX
Price
$11.01
$12.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
17.6K
138.2K
Earning Date
01-01-0001
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.62
$4.60
52 Week High
$12.09
$14.93

Technical Indicators

Market Signals
Indicator
JHS
ELTX
Relative Strength Index (RSI) 24.22 56.75
Support Level $11.01 $7.78
Resistance Level $11.40 $12.52
Average True Range (ATR) 0.10 1.17
MACD -0.03 -0.12
Stochastic Oscillator 4.62 30.02

Price Performance

Historical Comparison
JHS
ELTX

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: